Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth

Abstract Treatment-related skeletal complications are common in childhood cancer patients and survivors. Venetoclax is a BCL-2 inhibitor that has shown efficacy in hematological malignancies in adults and is being investigated in pediatric cancer clinical trials as a promising therapeutic modality....

Celý popis

Podrobná bibliografie

Hlavní autoři:	Lilly Velentza, Malin Wickström, Per Kogner, Claes Ohlsson, Farasat Zaman, Lars Sävendahl
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2023-05-01
Edice:	Scientific Reports
On-line přístup:	https://doi.org/10.1038/s41598-023-34965-4
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!